Wave Life Sciences posted a net loss of USD 69.36 million, widening from USD 50.47 million a year earlier.
Revenue fell 73.88% to USD 2.27 million, while research and development expenses rose 18% to USD 51.29 million.
General and administrative costs climbed 37.74% to USD 24.78 million; cash, cash equivalents and marketable securities totaled USD 490.6 million.
Pipeline updates and upcoming milestones
Dosing began in the Phase 2a multidose INLIGHT trial of obesity drug WVE-007; Phase 2 combination and post-incretin maintenance trials are targeted for the second half of 2026.
The FDA meeting is set for the end of summer 2026 on a potential accelerated approval pathway for AATD candidate WVE-006.
The WVE-008 CTA filing is still planned for the second half of 2026.
WVE•
